ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,427,146, issued on Sept. 30, was assigned to INVENTISBIO Co. LTD. (Shanghai).
"C-terminal SRC kinase inhibitors" was invented by Xing Dai (Shanghai), Yaolin Wang (Shanghai), Yueheng Jiang (Shanghai), Yanqin Liu (Shanghai), Zhe Shi (Shanghai), Zhenwu Wang (Shanghai), Zixing Han (Shanghai) and Liangshan Tao (Shanghai).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are novel C-terminal Srk Kinase (CSK) inhibitors, e.g., having Formula G, I, II, or III. Also provided are methods of preparing the novel CSK inhibitors and method of using the novel CSK inhibitors for treating diseases or disorder such as cancer or for promoting immune response ...